5Suppliers
0Customers
1Debt Items
12Related Chains

OKYO Pharma Limited Suppliers

TickerNameConfidenceEvidence
ON-TARGET-THERAPEUTICS-OTT ON-TARGET-THERAPEUTICS-OTT 92% License Agreement for Urcosimod On Target Therapeutics (OTT) and Tufts Medical Centre (TMC) entered into a license agreement on April 3, 2017
TUFTS-MEDICAL-CENTRE-TMC TUFTS-MEDICAL-CENTRE-TMC 92% License Agreement for Urcosimod On Target Therapeutics (OTT) and Tufts Medical Centre (TMC) entered into a license agreement on April 3, 2017
PANETTA-PARTNERS-LIMITED PANETTA-PARTNERS-LIMITED 90% On May 22, 2017, OTT entered into a license and sublicense agreement with Panetta Partners Limited, one of our principal stockholders
TMC TMC the metals company Inc. 90% We entered into a license agreement with TMC on May 1, 2018, relating to intellectual property and proprietary technology
TMC TMC the metals company Inc. 90% Reciprocal relationship from TMC graph: Reciprocal relationship from OKYO graph: We entered into a license agreement with TMC on May 1, 2018, relating to intellectual property and proprietary technology

OKYO Pharma Limited Customers

No clients on recordNo downstream customers found in our database for OKYO Pharma Limited.

OKYO Pharma Limited Debt Obligations

InstrumentDescriptionConfidenceEvidence
OKYO-DEBT Debt stack $185,795 90% Market cache reports total debt of $185,795.

OKYO Pharma Limited Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for OKYO Pharma Limited.

OKYO Pharma Limited Ownership

HolderNameConfidenceEvidence
OKYO-OWNER-WOODLINE-PARTNERS-LP Woodline Partners LP 90% 13F overlay lists Woodline Partners LP as top holder; 13 tracked holders.

OKYO Pharma Limited Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
BMYMP Bristol-Myers Squibb Co 100.00 2
TMC TMC the metals company Inc. 100.00 1 ['supplier']
BMY Bristol-Myers Squibb Company 100.00 2
TLSA Tiziana Life Sciences Ltd 100.00 1 ['receiving', 'spend']
NNVC NanoViricides, Inc. 50.00 2
HEPA Hepion Pharmaceuticals, Inc. 38.88 1 ['receiving']
CRDF Cardiff Oncology, Inc. 38.88 1 ['receiving']
SIGA SIGA Technologies, Inc. 38.88 1 ['receiving']
IMRN Immuron Limited 38.88 1 ['receiving']
VKTX Viking Therapeutics, Inc. 14.78 2
MANU Manchester 14.78 2
CSLLY CSL Limited 14.78 2